Ascendis Pharma AS Net Income
| ASND Stock | USD 222.15 4.77 2.19% |
As of the 9th of February, Ascendis Pharma shows the risk adjusted performance of 0.0632, and Mean Deviation of 2.09. Ascendis Pharma AS technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascendis Pharma AS information ratio, and the relationship between the downside deviation and value at risk to decide if Ascendis Pharma AS is priced correctly, providing market reflects its regular price of 222.15 per share. Given that Ascendis Pharma has jensen alpha of 0.2137, we suggest you to validate Ascendis Pharma AS's prevailing market performance to make sure the company can sustain itself at a future point.
Ascendis Pharma Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 18.273 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -340.3 M | -357.3 M | |
| Net Loss | -340.3 M | -357.3 M | |
| Net Loss | -524.9 M | -498.6 M | |
| Net Loss | (7.51) | (7.89) | |
| Net Income Per E B T | 0.91 | 0.78 |
Ascendis | Net Income | Build AI portfolio with Ascendis Stock |
Analyzing Ascendis Pharma's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Ascendis Pharma's current valuation and future prospects.
Latest Ascendis Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Ascendis Pharma AS over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ascendis Pharma AS financial statement analysis. It represents the amount of money remaining after all of Ascendis Pharma AS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ascendis Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascendis Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (378.08 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ascendis Net Income Regression Statistics
| Arithmetic Mean | (206,946,352) | |
| Coefficient Of Variation | (96.54) | |
| Mean Deviation | 177,090,255 | |
| Median | (130,097,000) | |
| Standard Deviation | 199,780,247 | |
| Sample Variance | 39912.1T | |
| Range | 587.3M | |
| R-Value | (0.87) | |
| Mean Square Error | 10070.4T | |
| R-Squared | 0.76 | |
| Slope | (34,568,030) | |
| Total Sum of Squares | 638594.4T |
Ascendis Net Income History
Other Fundumenentals of Ascendis Pharma AS
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ascendis Pharma Net Income component correlations
Ascendis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ascendis Pharma is extremely important. It helps to project a fair market value of Ascendis Stock properly, considering its historical fundamentals such as Net Income. Since Ascendis Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ascendis Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ascendis Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.52) | Revenue Per Share | Quarterly Revenue Growth 2.694 | Return On Assets | Return On Equity |
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Ascendis Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ascendis Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ascendis Pharma.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Ascendis Pharma on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Ascendis Pharma AS or generate 0.0% return on investment in Ascendis Pharma over 90 days. Ascendis Pharma is related to or competes with Ionis Pharmaceuticals, BridgeBio Pharma, Revolution Medicines, Roivant Sciences, Summit Therapeutics, Guardant Health, and Madrigal Pharmaceuticals. Ascendis Pharma AS, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs More
Ascendis Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ascendis Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ascendis Pharma AS upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.6 | |||
| Information Ratio | 0.0364 | |||
| Maximum Drawdown | 12.8 | |||
| Value At Risk | (4.38) | |||
| Potential Upside | 4.74 |
Ascendis Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascendis Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ascendis Pharma's standard deviation. In reality, there are many statistical measures that can use Ascendis Pharma historical prices to predict the future Ascendis Pharma's volatility.| Risk Adjusted Performance | 0.0632 | |||
| Jensen Alpha | 0.2137 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0377 | |||
| Treynor Ratio | (0.39) |
Ascendis Pharma February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0632 | |||
| Market Risk Adjusted Performance | (0.38) | |||
| Mean Deviation | 2.09 | |||
| Semi Deviation | 2.44 | |||
| Downside Deviation | 2.6 | |||
| Coefficient Of Variation | 1434.94 | |||
| Standard Deviation | 2.69 | |||
| Variance | 7.24 | |||
| Information Ratio | 0.0364 | |||
| Jensen Alpha | 0.2137 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0377 | |||
| Treynor Ratio | (0.39) | |||
| Maximum Drawdown | 12.8 | |||
| Value At Risk | (4.38) | |||
| Potential Upside | 4.74 | |||
| Downside Variance | 6.74 | |||
| Semi Variance | 5.95 | |||
| Expected Short fall | (2.27) | |||
| Skewness | (0.07) | |||
| Kurtosis | 0.0394 |
Ascendis Pharma AS Backtested Returns
Ascendis Pharma appears to be very steady, given 3 months investment horizon. Ascendis Pharma AS secures Sharpe Ratio (or Efficiency) of 0.0744, which signifies that the company had a 0.0744 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Ascendis Pharma AS, which you can use to evaluate the volatility of the firm. Please makes use of Ascendis Pharma's risk adjusted performance of 0.0632, and Mean Deviation of 2.09 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Ascendis Pharma holds a performance score of 5. The firm shows a Beta (market volatility) of -0.45, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Ascendis Pharma are expected to decrease at a much lower rate. During the bear market, Ascendis Pharma is likely to outperform the market. Please check Ascendis Pharma's value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to make a quick decision on whether Ascendis Pharma's price patterns will revert.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Ascendis Pharma AS has insignificant reverse predictability. Overlapping area represents the amount of predictability between Ascendis Pharma time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ascendis Pharma AS price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Ascendis Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | 0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 75.63 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ascendis Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ascendis Pharma AS reported net income of (378.08 Million). This is 210.78% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 166.22% higher than that of the company.
Ascendis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascendis Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics of similar companies.Ascendis Pharma is currently under evaluation in net income category among its peers.
Ascendis Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ascendis Pharma from analyzing Ascendis Pharma's financial statements. These drivers represent accounts that assess Ascendis Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ascendis Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 6.5B | 6.4B | 6.4B | 7.7B | 6.9B | 7.3B | |
| Enterprise Value | 6.2B | 6.6B | 6.8B | 8.0B | 7.2B | 7.6B |
Ascendis Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ascendis Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ascendis Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Ascendis Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Ascendis Pharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Ascendis Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ascendis Pharma's value.| Shares | Perceptive Advisors Llc | 2025-06-30 | 963.9 K | Amvescap Plc. | 2025-06-30 | 947.2 K | Wellington Management Company Llp | 2025-06-30 | 918.1 K | Polar Capital Holdings Plc | 2025-06-30 | 837.8 K | Ameriprise Financial Inc | 2025-06-30 | 588.1 K | Citadel Advisors Llc | 2025-06-30 | 587.3 K | Goldman Sachs Group Inc | 2025-06-30 | 538.3 K | American Century Companies Inc | 2025-06-30 | 530.8 K | Blackrock Inc | 2025-06-30 | 471.7 K | Ra Capital Management, Llc | 2025-06-30 | 10.3 M | Westfield Capital Management Company, L.p. | 2025-06-30 | 5.5 M |
Ascendis Fundamentals
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.0769 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 13.91 B | ||||
| Shares Outstanding | 61.1 M | ||||
| Shares Owned By Insiders | 0.75 % | ||||
| Shares Owned By Institutions | 99.25 % | ||||
| Number Of Shares Shorted | 3.16 M | ||||
| Price To Earning | (9.10) X | ||||
| Price To Book | 14.55 X | ||||
| Price To Sales | 20.99 X | ||||
| Revenue | 363.64 M | ||||
| Gross Profit | 561.21 M | ||||
| EBITDA | (290.02 M) | ||||
| Net Income | (378.08 M) | ||||
| Cash And Equivalents | 955.15 M | ||||
| Cash Per Share | 17.11 X | ||||
| Total Debt | 856.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 9.66 X | ||||
| Book Value Per Share | (3.37) X | ||||
| Cash Flow From Operations | (306.2 M) | ||||
| Short Ratio | 5.04 X | ||||
| Earnings Per Share | (4.52) X | ||||
| Price To Earnings To Growth | 10.25 X | ||||
| Target Price | 276.24 | ||||
| Number Of Employees | 1.02 K | ||||
| Beta | 0.43 | ||||
| Market Capitalization | 13.57 B | ||||
| Total Asset | 1.18 B | ||||
| Retained Earnings | (2.56 B) | ||||
| Working Capital | 153 M | ||||
| Current Asset | 125.65 M | ||||
| Current Liabilities | 11.45 M | ||||
| Net Asset | 1.18 B |
About Ascendis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascendis Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.52) | Revenue Per Share | Quarterly Revenue Growth 2.694 | Return On Assets | Return On Equity |
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.